RxDoctor Payments Data

Paula Song, MD

Internal Medicine · Atlanta, GANPI 1548793714

Payments from drug & device makers

$4,466in general payments, 2019–2025

Across 201 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$948
  • Amgen$799
  • Novartis$439
  • UCB, Inc.$414
  • Pfizer$299
  • AstraZeneca$292
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,39698%
  • Education$702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,466 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$98,122
Medicare patients
154
Services billed
2,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab47$338,302
Enbrel SureclickEtanercept34$254,388
Orencia ClickjectAbatacept25$141,305
Xeljanz XrTofacitinib Citrate17$118,497
ForteoTeriparatide23$104,021
OrenciaAbatacept12$70,073
Actemra ActpenTocilizumab12$52,887
Hydroxychloroquine Sulfate147$6,487
Mycophenolate Mofetil27$6,432
Atovaquone12$3,321
MethotrexateMethotrexate Sodium238$3,264
Leflunomide48$2,178
Colchicine27$1,948
Risedronate Sodium18$1,202
Gabapentin102$1,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$178$104,02123 claims
E.r. Squibb & Sons, L.L.C.Orencia$76$70,07312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →